Biogen Inc (BIIB) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Biogen Inc   (NASDAQ: BIIB)
 

Biogen Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BIIB Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) 1.93 % 5.15 % 10.17 % 10.9 %
Q / Q Revenue Growth (Q1 MRQ) 8.7 % -11.92 % -2.4 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 1.23 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) 0.47 % 1.16 % 2.09 % 2.61 %
Revenue 5 Year Average Growth -5.96 % 8.2 % 8.71 % 13.64 %


BIIB's Growth Comparisons in I. Quarter 2026




Comparing 1.93% year on year top-line growth in the first quarter 2026, Biogen Inc grew on the lower pace than the 5.15% growth in the Biotechnology & Pharmaceuticals industry and 10.17% Revenue improvement in the Healthcare sector. Slow first quarter sales, in the Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in Biogen Inc results which underperformed overall market.

Comparing the company's Revenue to the fourth quarter results, sales were higher by 8.7% . On the yearly basis, average annual sales growth for Biogen Inc is -5.96%, while S & P 500's including only Businesses with the first quarter 2026 earnings, average annual sales growth is 13.64% over the past five years.

BIIB Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product revenue net
1.49 %
-
Product revenue net U S
11.33 %
-
Product revenue net Rest of World
-6.13 %
-
MS Product
0.47 %
-
MS Product Revenues U S
14.07 %
-
MS Product Revenues Rest of World
-13.94 %
-
Fumarate
-16.35 %
-
Fumarate U S
17.78 %
-
Fumarate Rest of World
-44.84 %
-
TECFIDERA
-46.87 %
-
TECFIDERA U S
-21.11 %
-
TECFIDERA Rest of World
-53.04 %
-
VUMERITY
28.96 %
-
VUMERITY U S
31 %
-
VUMERITY Rest of World
17.97 %
-
Interferon
0.53 %
-
Interferon U S
0.08 %
-
Interferon Rest of World
1.18 %
-
AVONEX
-2.16 %
-
AVONEX U S
-0.09 %
-
AVONEX Rest of World
-6.01 %
-
PLEGRIDY
8.07 %
-
PLEGRIDY U S
0.83 %
-
PLEGRIDY Rest of World
12.99 %
-
TYSABRI
15.73 %
-
TYSABRI U S
20.42 %
-
TYSABRI Rest of World
10.51 %
-
Rare Disease Product Revenue
-1.08 %
-
Rare Disease Product Revenue U S
-2.81 %
-
Rare Disease Product Revenue Rest of World
0.12 %
-
SPINRAZA
-11.77 %
-
SPINRAZA U S
-7.9 %
-
SPINRAZA Rest of World
-13.99 %
-
SKYCLARYS
21.63 %
-
SKYCLARYS U S
3.91 %
-
SKYCLARYS Rest of World
43.98 %
-
QALSODY
109.68 %
-
QALSODY U S
40 %
-
QALSODY Rest of World
175 %
-
Biosimilars
0.77 %
-
Biosimilars Rest of World
3.23 %
-
BENEPALI
9.7 %
-
BENEPALI Rest of World
9.7 %
-
IMRALDI
4.64 %
-
IMRALDI Rest of World
4.64 %
-
FLIXABI
-19.85 %
-
FLIXABI Rest of World
-19.85 %
-
Other
88.44 %
-
Other U S
96.8 %
-
Other Rest of World
-92.31 %
-
ZURZUVAE
100 %
-
ZURZUVAE U S
99.64 %
-
ZURZUVAE Rest of World
-
-
Alzheimer s collaboration revenue
80.3 %
-
Alzheimer s Collaboration
80.3 %
-
Distributor One
5.41 %
-
Distributor Two
4.26 %
-
Genentech
26.32 %
-
Royalty Attributed To OCREVUS
9.83 %
-
Revenue from anti-CD20 therapeutic programs
10.81 %
-
Contract manufacturing revenue
-15.98 %
-
Royalty and other revenue
-11.82 %
-
Contract manufacturing royalty and other revenue
-15.82 %
-
Reportable Segment
1.93 %
-
Total
1.93 %
-


Growth Rates of BIIB's Income in the first quarter 2026


BIIB Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) 7.37 % 440.4 % 11.42 % 97.6 %
Sequential Operating Income Change (Q1 MRQ) 1.16 % -48.71 % -12.77 % 48.13 %
Y / Y Operating Income Growth (Q1 TTM) -4.32 % 997.37 % 30.99 % 40.67 %
Sequential Operating Income Growth (Q1 TTM) 1.3 % 229.64 % 4.94 % 20.86 %
Operating Income 5 Year Avg. Change -13.49 % -18.52 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) 32.85 % -78.38 % -14.37 % 90.69 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - - -63.62 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) -7.26 % -86.28 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q1 TTM) 6.11 % -58.33 % -4.66 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change -20.46 % -11.53 % 8.91 % -28.64 %

BIIB Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) 32.85 % -79.71 % -15.01 % 90.69 %
Q / Q Net Income Growth (Q1 MRQ) - -87.33 % 11.25 % 27.07 %
Y / Y Net Income Change (Q1 TTM) -7.26 % 103.17 % 15.41 % 57.33 %
Sequential Net Income Change (Q1 TTM) 6.11 % -7.85 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth -20.46 % -8.7 % 9.08 % 23.91 %

BIIB's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) 31.52 % -81.2 % -14.37 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - - -63.62 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) -7.98 % - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) 5.89 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth -18.7 % 37.43 % 8.91 % -28.64 %



BIIB EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) 31.1 % -82.35 % -15.01 % -28.64 %
Q / Q EPS Net Growth (Q1 MRQ) - -88.49 % 11.25 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) 5.79 % - -5.79 % 4.93 %
EPS Net 5 Year Avg. Change -18.73 % -8.7 % 9.08 % 23.91 %



Biogen Inc showed impressive 31.1% year on year rise in the first quarter to $2.15, despite the -82.35% inBiotechnology & Pharmaceuticals industry, Healthcare sector declined -15.01%. Slow first quarter 2026 income per share, in Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in the Biogen Inc results which underperformed overall market.

Comparing company's EPS to the fourth quarter results, income per share were higher by 8.7% . On the yearly basis, average annual income per share growth for Biogen Inc is -18.73%, while S & P 500's including only the businesses with the first quarter 2026 Results, average annual income per share growth is 23.91% over the past five years.

BIIB Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) 180.07 % 6160.46 % 46.64 % 48.62 %
Sequential Free Cash Flow Change (Q1 MRQ) 31.57 % -53.57 % -41.22 % 34.18 %
Y / Y Free Cash Flow Change (Q1 TTM) 4.6 % 14.36 % 19.59 % 60.27 %
Sequential Free Cash Flow Change (Q1 TTM) 18.92 % 17.17 % 5.78 % 15.75 %
Free Cash Flow 5 Year Avg. Change -11.66 % -13.86 % 0.41 % 1.92 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) 107.51 % - - 339.02 %
Sequential Net Cash Flow Change (Q1 MRQ) - 36.63 % - 216.68 %
Y / Y Net Cash Flow Change (Q1 TTM) -52.11 % 783.99 % - 209.43 %
Sequential Net Cash Flow Change (Q1 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 23.25 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) 8.7 % 32.26 % 10.58 % 120.03 %
Sequential Capital Expenditures Change (Q1 MRQ) -14.95 % -1.95 % -19.08 % 36.87 %
Y / Y Capital Expenditures Change (Q1 TTM) -33.74 % -4.97 % 7.77 % 109.38 %
Sequential Capital Expenditures Change (Q1 TTM) 2.21 % 7.49 % 1.52 % 23.05 %
Capital Expenditures 5 Year Avg. Change -17.21 % 9.64 % 8.6 % 14.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.